Results 1 to 6 of 6

Thread: BioArctic?s SC806

  1. #1

    BioArctic?s SC806

    Anyone have information into this?

  2. #2

    The U.S. Patent:,895,234

    "Spinal cord devices and methods for promoting axonal regeneration

    AbstractA spinal cord device comprises a body formed of a biocompatible, biodegradable matrix. The body includes proximal, cranial and distal, caudal surfaces for connection to two ends of an injured spinal cord after removal of an injured section and has through channels with openings in the cranial and caudal surfaces for connection of descending motor pathways and ascending sensory pathways. The device has a transversal diameter (D.sub.t), an anteroposterior diameter (D.sub.a) and a length (L), wherein D.sub.t is from 9 to 13 mm and the ratio anteroposterior diameter/transverse diameter (RAPT) is from 0.5 to 1.0 and wherein the position and dimension of the channels, RAPT value, and cranial surface area and/or caudal surface area of the device are adopted to the shape, level, dimension of white and gray matter, and size of the injured spinal cord for optimal connection between spinal cord tracts. Kits and methods employ such devices.

    Inventors:Frostell; Arvid (Stockholm, SE), Mattsson; Per (Taby, SE), Svensson; Mikael (Stockholm, SE)

    BioArctic Neuroscience AB
    Assignee:BIOARCTIC NEUROSCIENCE AB (Stockholm, SE)

    "BioArctic's potential regenerative treatment concept consists of a biodegradable device with an adjunctive drug Fibroblast Growth Factor 1 (FGF1) that stiumulates nerve regeneration and reduces scar formation. The project is inlicensed from Swenora Biotech AB and is based on research at Karolinska Institutet and Karolinska University Hospital.

    The treatment includes a surgical procedure in which a degradable implant containing peripheral nerves and growth factor FGF1 are operated into the damaged spinal cord to cause nerve regeneration (overgrowth) of nerve pathways over the area of injury. The device supports the guiding and regeneration of nerves and provides high anatomical precision in the surgical procedure, which aims at functional improvement of significant medical importance. The surgery is then followed by 18 months of rehabilitation."

  3. #3
    Any results or what they are seeing?

  4. #4
    Quote Originally Posted by MomNoah View Post
    Any results or what they are seeing?

    Study Type :Interventional (Clinical Trial)
    Estimated Enrollment :27 participants
    Intervention Model:Parallel Assignment
    Masking:None (Open Label)
    Primary Purpose:Treatment
    Official Title:An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Fibroblast Growth Factor 1 on a Biodegradable Device in Subjects With Traumatic Spinal Cord Injury
    Study Start Date :June 2015
    Estimated Primary Completion Date :December 2018
    Estimated Study Completion Date :May 2019

  5. #5

  6. #6
    Debating on CareCure is like participating in the special-olympics. You may win, but you're still disabled.

Similar Threads

  1. Replies: 2
    Last Post: 06-27-2008, 12:05 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts